OXiGENE Reports Commencement of Phase 2 Study of Fosbretabulin
September 17, 2014 at 16:02 PM EDT
OXiGENE, Inc. (Nasdaq: OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.